The nitric oxide-donating pravastatin, NCX 6550, inhibits cytokine release and NF-κB activation while enhancing PPARγ expression in human monocyte/macrophages

Pharmacological Research

Volumn 62, Issue 5, 2010, Pages 391-399

  Amoruso, Angela ^a   Bardelli, Claudio ^a   Fresu, Luigia Grazia ^a   Poletti, Elisa ^a   Palma, Alessandra ^a   Canova, Donata Federici ^a   Zeng, Hua Wu ^a,c   Ongini, Ennio ^b   Brunelleschi, Sandra ^a  

^a UNIVERSITY OF EASTERN PIEDMONT   (Italy)

^b Nicox Research Institute   (Italy)

^c SECOND MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

Cytokine release; Monocyte macrophages; NCX 6550; NF B; NO donor; PPAR

Indexed keywords

15 DEOXY DELTA12,14 PROSTAGLANDIN J2; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; ISOSORBIDE 5 NITRATE; NCX 6550; NITRIC OXIDE; NITRIC OXIDE DONATING PRAVASTATIN; NITROPRUSSIDE SODIUM; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PHORBOL 13 ACETATE 12 MYRISTATE; PRAVASTATIN; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ARTICLE; CELL ISOLATION; CYTOKINE RELEASE; DRUG MECHANISM; ENZYME LINKED IMMUNOSORBENT ASSAY; GEL MOBILITY SHIFT ASSAY; HUMAN; HUMAN CELL; MACROPHAGE; MONOCYTE; NORMAL HUMAN; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN TRANSPORT; REAL TIME POLYMERASE CHAIN REACTION; WESTERN BLOTTING;

ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; CYTOKINES; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; INTERLEUKIN-6; MACROPHAGES; MICE; MONOCYTES; NF-KAPPA B; NITRATES; NITRIC OXIDE; NITRIC OXIDE DONORS; PPAR GAMMA; PRAVASTATIN; SUPEROXIDES; TUMOR NECROSIS FACTOR-ALPHA;

EID: 77956897979     PISSN: 10436618     EISSN: 10961186     Source Type: Journal    
DOI: 10.1016/j.phrs.2010.07.006     Document Type: Article

References (41)

1. Burgaud J.L., Ongini E., Del Soldato P. Nitric oxide-releasing drugs. A novel class of effective and safe therapeutic agents. Ann NY Acad Sci 2002, 962:360-371.
2. Ignarro J.L., Napoli C., Loscalzo J. Nitric oxide donors and cardiovascular agents modulating the bioactivity of nitric oxide: an overview. Circ Res 2002, 90:21-28.
3. Miller M.R., Megson I.L. Recent development in nitric oxide donor drugs. Br J Pharmacol 2007, 151:305-321.
4. Ongini E., Impagnatiello F., Bonazzi A., Guzzetta M., Govoni M., Monopoli A., et al. Nitric oxide (NO)-releasing statin derivatives, a class of drugs showing enhanced antiproliferative and anti-inflammatory properties. Proc Natl Acad Sci 2004, 101:8497-8502.
5. Albina J.E. On the expression of nitric oxide synthase by human macrophages. Why no NO?. J Leukoc Biol 1995, 58:643-649.
6. Weinberg J.B., Misukonis M.A., Shami P.J., Mason S.N., Sauls D.L., Dittman W.A., et al. Human mononuclear phagocyte inducible nitric oxide synthase (iNOS): analysis of iNOS mRNA, iNOS protein, biopterin, and nitric oxide production by blood monocytes and peritoneal macrophages. Blood 1995, 86:1184-1195.
7. Rossiello M.R., Momi S., Caracchini R., Giannini S., Guglielmi G., Monopoli A., et al. A novel nitric oxide-releasing statin derivative exerts an antiplatelet/antithrombotic activity and inhibits tissue factor expression. J Thromb Haemostasis 2005, 3:2554-2562.
8. Emanueli C., Monopoli A., Kraenkel N., Meloni M., Gadau S., Campesi I., et al. Nitropravastatin stimulates reparative neovascularization and improves recovery from limb ischaemia in type-1 diabetic mice. Br J Pharmacol 2007, 150:873-882.
9. Dever G., Spickett C.M., Kennedy S., Rush C., Tennant G., Monopoli A., et al. NCX 6550 reduces splenocyte adhesion and reactive oxygen species generation in normal and atherosclerotic mice. J Pharmacol Exp Ther 2007, 320:419-426.
10. -/- mouse arteries via upregulation of P-selectin. Free Radic Biol Med 2008, 44:452-463.
11. Liao J.K., Laufs U. Pleiotropic effects of statins. Annu Rev Pharmacol Toxicol 2005, 45:89-118.
12. Palinski W., Tsimikas S. Immunomodulatory effects of statins: mechanisms and potential impact on atherosclerosis. J Am Soc Nephrol 2002, 13:1673-1681.
13. Wang C.Y., Liu P.Y., Liao J.K. Pleiotropic effects of statin therapy: molecular mechanisms and clinical results. Trends Mol Med 2008, 14:37-44.
14. Habib A., Shamsedden I., Nasrallah M.S., Antoun T.A., Nemer G., Bertoglio J., et al. Modulation of COX-2 expression by statins in human monocytic cells. FASEB J 2007, 21:1665-1674.
15. Yano M., Matsumara T., Senokuchi T., Ishii N., Murata Y., Takeda K., et al. Statins activate peroxisome proliferator-activated receptor γ through extracellular signal-regulated kinase 1/2 and p38 mitogen-activated protein kinase-dependent cyclooxygenase-2 expression in macrophages. Circ Res 2007, 100:1442-1451.
16. Amoruso A., Bardelli C., Gunella G., Fresu L.G., Ferrero V., Brunelleschi S. Quantification of PPAR-gamma protein in monocyte/macrophages from healthy smokers and non-smokers: a possible direct effect of nicotine. Life Sci 2007, 801:906-915.
17. Amoruso A., Bardelli C., Fresu L.G., Palma A., Vidali M., Ferrero V., et al. Enhanced peroxisome proliferator-activated receptor-gamma expression in monocyte/macrophages from coronary artery disease patients and possible gender differences. J Pharmacol Exp Ther 2009, 331:531-538.
18. Jiang C., Ting A.T., Seed B. PPARγ agonists inhibit production of monocyte inflammatory cytokines. Nature 1998, 391:82-86.
19. Paumelle R., Staels B. Peroxisome proliferator-activated receptors mediate pleiotropic actions of statins. Circ Res 2007, 100:1394-1395.
20. Amoruso A., Bardelli C., Gunella G., Ribichini F., Brunelleschi S. A novel activity for substance P: stimulation of peroxisome proliferator-activated receptor-γ in human monocytes and macrophages. Br J Pharmacol 2008, 154:144-152.
21. 1 receptors in human alveolar macrophages: superoxide anion production, cytokine release and involvement of NF-κB pathway. Br J Pharmacol 2005, 145:385-396.
22. T method. Methods 2001, 25:402-408.
23. Lavagno L., Gunella G., Bardelli C., Spina S., Fresu L.G., Viano I., et al. Anti-inflammatory drugs and tumor necrosis factor-α production from monocytes: role of transcription factor NF-κB and implication for rheumatoid arthritis therapy. Eur J Pharmacol 2004, 501:199-208.
24. Tepperman B.L., Chang Q., Soper B.D. Protein kinase C mediates lipopolysaccharide- and phorbol-induced nitric-oxide synthase activity and cellular injury in the rat colon. J Pharmacol Exp Ther 2000, 295:1249-1257.
25. 2 inhibits multiple steps in the NF-κB signalling pathway. Proc Natl Acad Sci 2000, 97:4844-4849.
26. Ptasinska A., Wang S., Zhang J., Wesley R.E., Danner R.L. Nitric oxide activation of peroxisome proliferator-activated receptor gamma through a p38 MAPK signalling pathway. FASEB J 2007, 21:950-961.
27. Momi S., Impagnatiello F., Guzzetta M., Caracchini R., Guglielmini G., Olivieri R., et al. NCX 6560, a nitric oxide-releasing derivative of atorvastatin, inhibits cholesterol biosynthesis and shows anti-inflammatory and anti-thrombotic properties. Eur J Pharmacol 2007, 570:115-124.
28. Libby P., Ridker P.M., Maseri A. Inflammation and atherosclerosis. Circulation 2002, 105:1135-1141.
29. Venketaraman V., Talaue M.T., Dayaram Y.K., Peteroy-Kelly M.A., Bu W., Connell N.D. Nitric oxide regulation of l-arginine uptake in murine and human macrophages. Tubercolosis 2003, 83:311-318.
30. Carreras M.C., Pargament G.A., Catz S.D., Poderoso J.J., Boveris A. Kinetics of nitric oxide and hydrogen peroxide production and formation of peroxynitrite during the respiratory burst in human neutrophils. FEBS Lett 1994, 34:65-68.
31. Hölschermann H., Schuster D., Parviz B., Haberbosch W., Tillmanns H., Heidrun M. Statins prevent NF-κB transactivation independently of the IKK-pathway in human endothelial cells. Atherosclerosis 2006, 185:240-245.
32. Jarvisalo M.J., Toikka J.O., Vasankari T., Mikkola J., Viikari J.S., Hartiala J.J., et al. HMG CoA reductase inhibitors are related to improved systemic endothelial function in coronary artery disease. Atherosclerosis 1999, 147:237-242.
33. Laufs U., La Fata V., Plutzky J., Liao J.K. Upregulation of endothelial nitric oxide synthase by HMG CoA reductase inhibitors. Circulation 1998, 97:1129-1135.
34. Wassmann S., Laufs U., Baumer A.T., Muller K., Konkol C., Sauer H., et al. Inhibition of geranylgeranylation reduces angiotensin II-mediated free radical production in vascular smooth muscle cells: involvement of angiotensin AT1 receptor expression and Rac1 GTPase. Mol Pharmacol 2001, 59:646-654.
35. Hall C.N., Garthwaite J. What is the real physiological NO concentration in vivo?. Nitric Oxide 2009, 21:92-103.
36. Blake G.J., Ridker P.M. Inflammatory biomarkers and cardiovascular risk prediction. J Intern Med 2002, 252:283-294.
37. Peng H.B., Libby P., Liao J.K. Induction and stabilization of IκBα by nitric oxide mediates inhibition of NF-κB. J Biol Chem 1995, 270:14214-14219.
38. Amoruso A., Gunella G., Rondano E., Bardelli G., Fresu L.G., Ferrero V., et al. Tabacco smoke affects expression of peroxisome proliferator-activated receptor-gamma in monocyte/macrophages of patients with coronary heart disease. Br J Pharmacol 2009, 58:1272-1284.
39. Zelvyte I., Dominaitiene R., Crisby M., Janciauskiene S. Modulation of inflammatory mediators and PPARγ and NF-κB expression by pravastatin in response to lipoproteins in human monocytes in vitro. Pharmacol Res 2002, 45:147-154.
40. Gonon A.T., Bulhak A., Labruto F., Sjoquist P.O., Pernow J. Cardioprotection mediated by rosiglitazone, a peroxisome proliferator-activated receptor gamma ligand, in relation to nitric oxide. Basic Res Cardiol 2007, 102:80-89.
41. Sorrentino S.A., Bahlmann F.H., Besler C., Muller M., Schultz S., Kirchhoff N., et al. Oxidant stress impairs the in vivo reendothelialization capacity of endothelial progenitor cells from patients with type 2 diabetes mellitus. Restoration by the Peroxisome Proliferator-Activated Receptor-γ agonist rosiglitazone. Circulation 2007, 116:163-173.